Navigation Links
Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology

NASHVILLE, Tenn. and KNOXVILLE, Tenn., Feb. 10 /PRNewswire/ -- Nashville-based Cumberland Emerging Technologies, Inc. (CET) and the University of Tennessee Research Foundation (UTRF) today announced they have entered into a license agreement for a promising new asthma treatment discovered at the University of Tennessee Health Science Center. Under the agreement, CET is providing formulation, grant funding, regulatory and product development assistance in exchange for rights to commercialize the new technology.

(Photo: )

The joint development project has received more than $190,000 in grant funding, including a recent Phase I grant award of nearly $112,000 from the National Institutes of Health under the Small Business Technology Transfer program. Additional grant funding was provided by the University of Tennessee Research Foundation and CET. The grants will support continued study of a technology designed to prevent remodeling of airway smooth muscle and thereby reduce or eliminate asthmatic reaction in pediatric patients.

Airway remodeling occurs when the cells or muscles that line the airway become inflamed and can result in decreased lung function. Currently, there is no treatment available that prevents remodeling of the airway smooth muscle. According to the National Center for Health Statistics, more than 6.8 million children under age 17 in the United States suffer from asthma.

"Our mission at UTRF is to support the research enterprise and find ways to take research results to the marketplace in a way that benefits society," said Fred Tompkins, President of UTRF. "With the expertise and commitment of CET's development team, we are one step closer to a treatment that could reduce -- and even prevent -- asthma attacks in children. We are delighted to have their support as we continue this promising research."

University of Tennessee College of Medicine researcher and primary investigator Dr. Dukhee Betty Lew will conduct non-clinical studies to identify appropriate dosing for the drug. Upon completion of the non-clinical program, CET, the University of Tennessee (UT) and UTRF plan to seek additional grant funding to study the drug's efficacy in patients.

The joint development project is a result of the 2006 collaboration agreement between CET and UTRF to further research efforts at the university by leveraging CET's technology development and regulatory expertise.

"Licensing this technology is an important milestone for CET," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals and CET. "Not only are we adding a promising new product candidate to our development pipeline, we are also providing researchers with the resources necessary to advance this important work. This is precisely what we envisioned when we created CET to bridge the gap between the research laboratory and the commercial marketplace."

The University of Tennessee Research Foundation, a Tennessee not-for-profit corporation, helps turn the ideas and discoveries that emerge from the University of Tennessee into products and services that benefit society. In addition to supporting the growth of the UT research enterprise and commercializing the resulting inventions, UTRF champions entrepreneurship and drives state and regional technology-based economic development. UTRF serves all seven of the UT campuses and institutes across the state. For more information, visit

Cumberland Emerging Technologies, Inc. is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the Tennessee Technology Development Corporation. The mission of CET ( is to bring biomedical technologies and products conceived at regional research centers to the marketplace. CET manages the development and commercialization process for select projects and provides intellectual property, regulatory, manufacturing and marketing expertise that is critical for successful new biomedical products. CET's Life Sciences Center located in Nashville, Tennessee provides laboratory space, equipment and infrastructure to early- stage life sciences companies.

SOURCE Cumberland Emerging Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Bionovo to Present at A.G. Edwards 2nd Annual Emerging Growth Conference 2007
7. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
8. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
9. Neurocrine Biosciences to Present at the A.G. Edwards Annual Emerging Growth Conference
10. Luminex Corporation to Present at Americas Growth Capital Emerging Growth Conference
11. Project on Emerging Nanotechnologies and Consumers Union collaborate on ConsumersTalkNano
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... Imagine ... Jurassic World: The Exhibition, opening in March 2016 at Melbourne Museum in Melbourne, ... tour including several North American tour dates. The Exhibition is based on Universal ...
(Date:11/30/2015)...  Champions Oncology, Inc. (CSBR), engaged in the development ... development and use of oncology drugs, today announced that ... presenting at the LD MICRO Investor Conference on Wednesday, ... The conference, held at the Luxe Sunset Bel Air ... will feature 200 small/micro-cap companies and is expected to ...
(Date:11/30/2015)... -- Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, ... Inc., a leading genome informatics company offering highly accurate, ... San Diego -based company has 14 ... Ashley Van Zeeland , Ph.D., who is now ... the deal were not disclosed. Van ...
(Date:11/30/2015)... Florida , November 30, 2015 ... specializing in the development of innovative peptide and gene-based ... metastatic disease, today announced it will be presenting at ... on December 1, 2015 at 2.30 PM PT. Dr. ... and Strategic Advisor will be giving the presentation and ...
Breaking Biology Technology:
(Date:11/30/2015)... , Nov. 30, 2015  BIOCLAIM announced ... finalist in this year,s Fierce Innovation Awards:  Healthcare Edition, ... FierceHealthIT , FierceHealthcare , ... as a finalist in the category of "Privacy ... --> --> ...
(Date:11/26/2015)... 2015 Research and Markets ( ) ... Sensors - Technology and Patent Infringement Risk Analysis" ... --> Fingerprint sensors using capacitive technology ... fingerprint sensor vendor Idex forecasts an increase of 360% ... devices and of the fingerprint sensor market between 2014 ...
(Date:11/20/2015)... Connecticut , November 20, 2015 ... authentication company focused on the growing mobile commerce market ... CEO, Gino Pereira , was recently interviewed on ... interview will air on this weekend on Bloomberg ... Latin America . --> NXTD ) ("NXT-ID" ...
Breaking Biology News(10 mins):